← All trials
NCT05949385
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 12, 2023
- Primary completion
- Feb 7, 2024
- Completion date
- Feb 16, 2024
- First posted
- Jul 18, 2023
- Last posted
- Jul 18, 2023
- Enrollment
- 16
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hangzhou Zenshine Pharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.